EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 287 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Adjuvant Pembrolizumab Prolongs DFS Among Patients with High-Risk Muscle Invasive Urothelial... September 25, 2024 Mom Walks In To Comfort Scared Son After Surgery And Sees... June 26, 2019 How to Find Reliable and Affordable Transportation During Cancer January 23, 2024 確診癌症後患者應如何面對悲傷 July 7, 2020 Load more HOT NEWS First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... ‘A significant step forwards’ – treating patients with advanced biliary tract... Plant-Based Diets and a New Treatment Combination for Prostate Cancer: Research...
